Boehringer Ingelheim Metabolic Deal History & Licensing Activity
Boehringer Ingelheim Metabolic is a large pharma headquartered in Germany. Over the past three years, Boehringer Ingelheim Metabolic has been involved in 3 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Boehringer Ingelheim Metabolic Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Boehringer Ingelheim Metabolic in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Immunitas inflammatory/immunology lead asset | Boehringer Ingelheim | Antibodies | Discovery | collaboration | May 15, 2026 |
| CT-155 | Click Therapeutics | Other | Phase 3 | other | Apr 15, 2026 |
Boehringer Ingelheim Metabolic Pipeline Focus
Therapeutic areas and modalities where Boehringer Ingelheim Metabolic is most active based on deal history and clinical trial data.
Therapeutic Areas
Boehringer Ingelheim Metabolic Strategic Signals
Key indicators of Boehringer Ingelheim Metabolic's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Boehringer Ingelheim Metabolic Clinical Pipeline
Boehringer Ingelheim Metabolic has 50 active clinical trials across 5 development phases.
3
Unknown
3
Phase 4
23
Phase 1
9
Phase 2
12
Phase 3
See How Your Asset Matches Boehringer Ingelheim Metabolic's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Boehringer Ingelheim Metabolic Licensing & Deal Activity
Boehringer Ingelheim Metabolic is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Boehringer Ingelheim Metabolic ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Boehringer Ingelheim Metabolic include Solid Tumors (7 deals and trials), Metabolic (6 deals and trials), Cardiovascular (4 deals and trials), and Neurology (3 deals and trials). In terms of modality, Boehringer Ingelheim Metabolic has shown particular interest in antibodies, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Boehringer Ingelheim Metabolic and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Boehringer Ingelheim Metabolic's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.